Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLTAIRE-TAI: BI 695501 Autoinjector vs Prefilled Syringe PK Study
NCT02899338Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and 4 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to 1368 Hours, Maximum Measured Concentration at 1368 hours and 1 more. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT02899338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899338.